VEGF靶向治疗及其生物标志物在晚期结直肠癌中的研究进展

VEGF-targeted therapy for metastatic colorectal cancer and related biomarkers:recent advances

结直肠癌(CRC)是世界范围内癌症发病与致死的主要因素,近几年分子靶向治疗的临床应用为晚期结直肠癌治疗带来了曙光。贝伐珠单抗被批准应用于一线和二线晚期结直肠癌的治疗,促使了以血管内皮生长因子(VEGF)为作用靶点的靶向治疗药物不断涌现,并在临床试验中取得显著疗效。笔者就VEGF靶向治疗及其生物标志物在晚期结直肠癌中的研究进展进行综述。

Colorectal cancer（CRC） is a major contributor to cancer morbidity and mortality worldwide.Recently,the clinical application of molecular targeting therapy brings hope for treatment of metastatic CRC（m CRC）.Following the approval of bevacizumab as first-and second-line treatment of m CRC,the therapeutic agents targeting vascular endothelial growth factor（VEGF） have been emerging constantly,and also shown signii cant efficacy in clinical trials.In this paper,the authors address the progress in VEGF-targeted therapy and the related biomarkers for m CRC.